MAT-GLB-2000992 V 3.0 March 2021

At Sanofi, our passion is to prevent, treat and cure illness and disease throughout life. We are driven to improve the health of communities and to find new solutions for patients by combining breakthrough science with advanced technology.

Inspired by the resilience of our patients and strengthened by our heritage, we are always working for new ways to fight chronic, complex and rare diseases with medicines that offer hope for patients and the future of healthcare.

SANOFI

Who we are

AROUND THE WORLD

We are present in
~ 90 countries

Healthcare solutions available in more than
170 countries

OUR TEAMS

~ 100,000
employees

46.8%
women

53.2%
men

Source: Form 20-F 2020

2020 key figures

COMPANY SALES



BUSINESS NET INCOME

€7,347m
+9.6%

BUSINESS EARNINGS PER SHARE

€5.86
+9.2%

All growth rates at constant exchange rates

Source: Press release issued on February 5, 2021

All growth rates at constant exchange rates

Play to Win

In December 2019, CEO Paul Hudson unveiled the company's strategic framework, **Play to Win**, to **drive growth and unleash fresh inspiration** across all Sanofi's activities.

A STRATEGY BASED ON FOUR KEY PRIORITIES

Focus on growth

Portfolio prioritization to strengthen profile

Lead with innovation

Bring transformative therapies to patients

Accelerate efficiency

Decisive actions to expand margins

Reinvent how we work

Empowerment and accountability

Our key growth drivers

DUPIXENT® (DUPILUMAB)

Ambition to deliver strong growth, as Dupixent® gains approval in an expanding number of type 2 inflammation indications

VACCINES

Expected to deliver growth through a **wide portfolio**, **market expansion and new launches**

PIPELINE

Prioritize and accelerate portfolio of potentially **transformative therapies**

Note: Dupixent® (dupilumab) is a product in collaboration with Regeneron, Dupixent® might not be approved in markets where you live, please check locally.

Global Business Unit (GBU) organization[1]

3 CORE GBUs FOCUSED ON PRIORITIZED PORTFOLIO

Specialty Care

- Immunology
- Rare Diseases / Rare Blood Disorders
- Neurology / Multiple Sclerosis
- Oncology

General Medicines

- Diabetes
- Cardiovascular
- Established Products

Vaccines

- Influenza vaccines
- Polio Pertussis & Hib, Boosters
- Meningitis, others

STANDALONE GBU

Consumer Healthcare

- Allergy, Cough & Cold
- Pain
- Digestive
- Nutritionals

Note: [1] Subject to consultation with social partners and works councils

A new Executive Committee aligned with priorities

Paul Hudson
Chief Executive Officer

Natalie Bickford
Human Resources

Olivier Charmeil
General Medicines

Jean-Baptiste Chasseloup de Chatillon
Finance

Karen Linehan
Legal & General Counsel

Thomas Triomphe
Vaccines

Philippe Luscan
Industrial Affairs

Julie van Ongevalle
Consumer Healthcare

John Reed
Research & Development

Arnaud Robert
Digital

Bill Sibold
Specialty Care

Our Research and Development teams push boundaries

R&D is fully engaged in a major transformation process:

- Focus research on priority therapeutic areas in Specialty Care and Vaccines
- Leverage new drug discovery platforms and modalities
- Accelerate development to deliver breakthrough medicines and vaccines to patients

Long-term objectives for our pipeline over the next 5-10 years[1]:

15,000+
people
involved in R&D[2]

Over €5.5bn
invested
in R&D in 2020[2]

84
projects
in clinical development[3]

80%
of products
first or best-in-class

70%
of project derived
from in-house research

70%
biologics

Notes: [1] Objectives: approximate figures | [2] Form 20-F 2020 | [3] Presentation issued on February 5, 2021

Focusing on potentially transformative therapies



DUPIXENT® (DUPILUMAB)[1]

Transformative medicine for type 2 inflammatory diseases

- Approved for different patient populations with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps[4]
- Potential in other respiratory and dermatology indications, currently under investigation

FITUSIRAN & EFANESOCTOCOG ALPHA[2]

Great convenience for hemophilia patients

- Fitusiran: potential to provide a monthly dose that delivers high efficacy for hemophilia A and B
- Efanesoctocog Alpha: potential to deliver high protection from bleeds for people with hemophilia A

AMCENESTRANT

Potential new therapy for hormone-receptor-positive breast cancer

- Potential once-daily oral treatment

VENGLUSTAT

Potential product for multiple rare diseases

- Oral therapy with potential in treating lysosomal storage disorders and other rare but more common disorders

NIRSEVIMAB[3]

Potential prevention against respiratory syncytial virus

- An innovative immunization for immediate and sustained protection of infants

TOLEBRUTINIB

Potential disease-modifying therapy for multiple sclerosis

- Oral treatment with potential to address inflammation and disability drivers in the brain

Notes: [1] In collaboration with Regeneron | [2] In collaboration with Swedish Orphan Biovitrum (Sobi) | [3] In collaboration with AstraZeneca | [4] Dupixent® might not be approved in the markets where you live, please check locally
Fitusiran, efanesoctocog alpha, amcenestrant, venglustat, nirsevimab and tolebrutinib are under investigation and not approved by any regulatory authority in the world
Source: Form 20-F 2020

Manufacturing is key to our business

Industrial Affairs is an essential link between Research and Development and patients.

The Industrial Affairs transformation supports our latest portfolio developments:

- **Biologics** — Ramping up capacities to expand our technological expertise
- **Performance** — Delivering industrial excellence
- **Digitalization** — Making the factory of the future a reality

Our industrial network embraces all technologies and supports all Global Business Units:

SPECIALTY CARE

Biologics and injectable technologies

VACCINES

Global leader

GENERAL MEDICINES

Wide range of established products

CONSUMER HEALTHCARE (CHC)

OTC solutions

33,000+
employees[1]

A global network of
69
production sites[1]

~€1bn
invested every year to transform our industrial network

>4.8bn
units of pharmaceuticals, CHC products and vaccines sold in 2020

Note: [1] Form 20-F 2020

EUROAPI - Creating a major European active pharmaceutical ingredients company[1]

NEW INDUSTRY CHAMPION

Standalone company combining our API activities with six of our European API production sites

Expected sales of **€1bn** by 2022

Expected to **rank world #2**[2]

Headquartered in **France**

3,100+ employees with a presence in **13 countries** and sales in **80+ countries**

Karl Rotthier appointed future Chief Executive Officer

SIX EUROPEAN MANUFACTURING SITES



STRONG EUROPEAN SUPPLIER REBALANCING INDUSTRY DEPENDENCE ON ASIA

Source: Press release issued on January 12, 2021
API: active pharmaceutical ingredient
Note: [1] Subject to consultation with social partners and works councils | [2] Company estimates based on comparison with data published in annual reports of major API companies

Digitalization accelerates our transformation

R&D

Accelerate the R&D cycle, clinical trials and regulatory reviews, improve productivity and enable better disease understanding

- Digital technologies
- Advanced data analytics
- Artificial intelligence

INDUSTRIAL AFFAIRS



Factories powered by digital and user-oriented solutions contribute to a sustainable manufacturing system, driving higher productivity, agility and flexibility

- Integrated industrialization
- Connected factories
- Connected teams and operations
- Intelligent quality
- Real-time supply chain

Sanofi's renewed contract with society

Affordable access

Create a **Global Health Unit that gives access and supply continuity to 30 essential life-changing medicines**[1] at no-profit to the world's 40 poorest countries

Donate 100,000 vials to treat Rare Disease patients every year free of charge[2]

Develop a global access plan for all new products with the goal to make available our new innovation within 2 years of the launch in the U.S.

R&D for unmet needs

Vulnerable communities

Eradicate Polio

Eradicate Sleeping disease in humans by 2030

Develop innovative medicines to eliminate cancer deaths in children

Efficiency &Sustainability

Healthy planet

100% blister-free vaccines by 2027

100% eco-design for all our new products by 2025

100% renewable energy for our electricity in all our sites by 2030

100% carbon neutral car fleet in 2030[3]

Beyond the work place

An inclusive work place

A senior leadership community representative of society by 2025

Social & economic engagement in all communities where we operate

From leaders to citizens – CSR is embedded in our leaders' career development path

1.As defined by the World Health Organization
2.Donation with no commercial intent
3.Scope: Vehicles fleet directly controlled (leased/acquired) by Sanofi and during the usage phase by Sanofi

Sanofi committed to the fight against COVID-19



Focusing on the development of two complementary vaccine approaches

Recombinant protein-based COVID-19 vaccine candidate

- Joining forces with GSK which will contribute its pandemic adjuvant technology to the vaccine
- Collaborating with BARDA which provides $2.1bn funding

Novel mRNA COVID-19 vaccine candidate

- Collaborating with Translate Bio

Ensuring global access to potential recombinant vaccine

Pre-orders signed by Sanofi and GSK with major countries and regions

- Europe: up to 300 million doses
- U.S.: initial 100 million doses, further option for an additional 500 million doses
- UK: up to 60 million doses
- Canada: up to 72 million doses

Sanofi and GSK to support COVAX Facility

- COVAX Facility to secure successful and equitable access to COVID-19 vaccines worldwide: up to 200 million doses

Continuous commitment to patients and the society

- Largely **maintained clinical trials**
- **Ensured manufacturing** and delivery of medicines and vaccines
- **Supported patients,** healthcare workers and health authorities
- **Investigating existing medicine** as potential treatment for COVID-19
- **Provide manufacturing support** to BioNTech and Johnson & Johnson for their COVID-19 vaccines to help address global supply demands

Note: BARDA: Biomedical Advanced Research And Development Authority; mRNA: messenger ribonucleic acid
Source: Q1 2020 investor presentation, press releases issued on October 28 and 29, 2020 and on January 27 and February 22, 2021

Recommendations

This corporate presentation is available for all employees in the Sanofi Company. It may be used internally or externally for presentations of the Company, either in whole or in part, as needed.

The information is taken from Form 20-F 2020, annual results 2020 and press releases.

Further information is available on www.sanofi.com

SANOFI
CORPORATE COMMUNICATIONS

54, rue La Boétie
75008 Paris, France
+33 (0)1 53 77 40 00

Forward-Looking Statements

This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, the impact of global disruptions, including pandemics, cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Photo credits:
Cover: Monkeybusinessimages/GettyImages; p2 : Monkeybusinessimages/GettyImages; p5 : Unspalsh@nci, Sanofi, Stocklib, Unspalsh@christiannkoepke; p6 : Unspalsh@brookecagle, Unspalsh@cdc, Christian Vorhofer; p7 : Stocklib, Stocklib, Unspalsh@nci, Unspalsh@xaviermoutonphotographie; p8 : Jean Chiscano, Christel Sasso/Capa pictures, Jean Chiscano, Jean Chiscano, Christel Sasso/Capa pictures, Nobert Domy/Sanofi Pasteur, Christel Sasso/Capa pictures, Christel Sasso/Capa pictures, Shannon Power, Christel Sasso/Capa pictures, Sanofi Genzyme; p9 : Rost-9D/GettyImages; p10 : Sanofi : 2020_06_02_oncology_original; p11 : Sanofi : Aug 16 2019 - Sanofi 8 NYA - 0018; p13 : Stocklib, Stocklib; p14 : Solstock/GettyImages; p15 : Naeblys/GettyImages